What are the medical insurance reimbursement conditions for entrectinib?

Entrectinib is a targeted drug used to treat specific types of cancer, mainly targeting solid tumors carrying NTRK fusion genes and ROS1-positive non-small cell lung cancer (NSCLC). With the gradual confirmation of its efficacy, entrectinib has been launched in China and has been included in the scope of medical insurance reimbursement, providing eligible patients with a more convenient treatment option. It is very important for patients to understand the medical insurance reimbursement conditions of this drug, which not only helps to reduce the cost of treatment, but also ensures that effective treatment can be obtained as early as possible if the conditions are met.

First of all, the medical insurance reimbursement conditions for entrectinib clearly stipulate that patients must be 1.12 years old and above, and be diagnosed as patients with solid tumors carrying NTRK fusion genes or patients with ROS1-positive non-small cell lung cancer through fully validated testing methods. Specifically, such patients must have locally advanced, metastatic disease, or a situation where severe complications from surgical resection are likely. If the patient's condition meets the above conditions and no known acquired resistance mutations occur, the patient is eligible for treatment with entrectinib. In addition, entrectinib is also suitable for patients who have no other effective alternative treatments or who have failed existing treatments.

For patients with RO1-positive non-small cell lung cancer, entrectinib also provides a powerful treatment option. Such patients can apply for the use of entrectinib when their disease is confirmed to be locally advanced or metastatic NSCLC, and the treatment costs will be reimbursed through medical insurance. The effectiveness of entrectinib in ROS1-positive lung cancer also brings new treatment hope to patients, especially those who have failed previous treatments, which means a new treatment opportunity.

Reference materials:https://www.roche.com/products/rozlytrek